{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:54:46Z","timestamp":1791021286608,"version":"4.1.0"},"reference-count":170,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004070","name":"Khalifa University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jare.2026.08.030","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:40:13Z","timestamp":1786322413000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["From KRAS inhibition to tumor adaptation: mechanistic layers of resistance and therapeutic strategies"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6234-2324","authenticated-orcid":false,"given":"Rawan","family":"Salih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0377-7883","authenticated-orcid":false,"given":"Fazila","family":"Sirajudeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Rahmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2026.08.030_b0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12943-024-02218-1","article-title":"The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy","volume":"24","author":"Ma","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jare.2026.08.030_b0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","article-title":"Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival","volume":"31","author":"Varghese","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jare.2026.08.030_b0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0092-8674(82)90100-3","article-title":"Isolation of a transforming sequence from a human bladder carcinoma cell line","volume":"29","author":"Shih","year":"1982","journal-title":"Cell"},{"key":"10.1016\/j.jare.2026.08.030_b0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/304507a0","article-title":"Activation of Ki-ras 2 gene in human colon and lung carcinomas by two different point mutations","volume":"304","author":"Capon","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.08.030_b0025","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS\u2013MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2026.08.030_b0030","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.08.030_b0035","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jare.2026.08.030_b0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","article-title":"Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors","volume":"6","author":"Lee","year":"2022","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41698-024-00644-4","article-title":"Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC","volume":"8","author":"Sisoudiya","year":"2024","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0050","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf153","article-title":"KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape","volume":"30","author":"Frisch","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.jare.2026.08.030_b0055","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.08.030_b0060","first-page":"26","article-title":"Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma","volume":"8","author":"Yousef","year":"2024","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111717","article-title":"The current understanding on the impact of KRAS on colorectal cancer","volume":"140","author":"Meng","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jare.2026.08.030_b0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/path.6407","article-title":"Cellular origins of mucinous ovarian carcinoma","volume":"266","author":"Meagher","year":"2025","journal-title":"J Pathol"},{"key":"10.1016\/j.jare.2026.08.030_b0075","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/oncolo\/oyac179","article-title":"KRAS mutation variants and co-occurring PI3K pathway alterations impact survival for patients with pancreatic ductal adenocarcinomas","volume":"27","author":"Diehl","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jare.2026.08.030_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00432-025-06118-9","article-title":"Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China","volume":"151","author":"Wu","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0085","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.3390\/cancers14235921","article-title":"Mutational status of SMAD4 and FBXW7 affects clinical outcome in TP53\u2013mutated metastatic colorectal cancer","volume":"14","author":"Lahoz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2026.08.030_b0090","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41586-025-09025-8","article-title":"Geographic and age variations in mutational processes in colorectal cancer","volume":"643","author":"D\u00edaz-Gay","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.08.030_b0095","first-page":"26","article-title":"Research progress on KRAS mutations in colorectal cancer","volume":"7","author":"Cefal\u00ec","year":"2021","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.jare.2026.08.030_b0100","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35783","article-title":"Advances in the treatment of KRASG12C mutant non\u2013small cell lung cancer","volume":"131","author":"Shaverdashvili","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.jare.2026.08.030_b0105","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2026.08.030_b0110","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10120-019-00972-6","article-title":"KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study","volume":"22","author":"Hewitt","year":"2019","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.jare.2026.08.030_b0115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2024.10.026","article-title":"KRAS mutations in endometrial cancers: possible prognostic and treatment implications","volume":"191","author":"Kilowski","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0120","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-23-2819","article-title":"Clinical and genomic landscape of RAS mutations in gynecologic cancers","volume":"30","author":"Son","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0125","article-title":"TP53 and KRAS co-mutations are associated with worse outcomes in mucinous ovarian carcinomas","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.12688\/f1000research.126337.1","article-title":"Role of RAS signaling in ovarian cancer","volume":"11","author":"Therachiyil","year":"2022","journal-title":"F1000Res"},{"key":"10.1016\/j.jare.2026.08.030_b0135","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1538-7445.AM2024-5064","article-title":"Wild type KRAS amplification as de novo oncogenic driver in non-small cell lung cancer","volume":"84","author":"Ricciuti","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0140","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41591-018-0022-x","article-title":"Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition","volume":"24","author":"Wong","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jare.2026.08.030_b0145","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1186\/s12967-025-06864-x","article-title":"KRAS amplification in colorectal cancer: correlations with clinicopathological features and prognosis in patients and prediction of response to targeted therapy","volume":"23","author":"Yang","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.jare.2026.08.030_b0150","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.3390\/cancers14194933","article-title":"Clinical and molecular features of KRAS-mutated lung cancer patients treated with immune checkpoint inhibitors","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jare.2026.08.030_b0155","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251323985","article-title":"Immunotherapy in advanced, KRAS G12C-mutant non-small-cell lung cancer: current strategies and future directions","volume":"17","author":"Ghazali","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0160","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/2767-9764.CRC-24-0376","article-title":"Molecular differences in pancreatic ductal adenocarcinomas from black versus white patients","volume":"5","author":"Mandal","year":"2025","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jare.2026.08.030_b0165","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13046-025-03444-1","article-title":"Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?","volume":"44","author":"Fu","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"issue":"1614\u20131629","key":"10.1016\/j.jare.2026.08.030_b0170","first-page":"e5","article-title":"Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer","volume":"42","author":"McIntyre","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2026.08.030_b0175","article-title":"KRASG12D-mutated metastatic colorectal cancer: clinical, molecular, immunologic, and prognostic features of a new emerging targeted alteration","volume":"8","author":"Moretto","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s44319-025-00641-z","article-title":"FOXO1 links KRAS G12D and G12V alleles to glutamine and nitrogen metabolism in colorectal cancer","volume":"27","author":"Ber","year":"2025","journal-title":"EMBO Rep"},{"key":"10.1016\/j.jare.2026.08.030_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115444","article-title":"KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation","volume":"44","author":"Budagyan","year":"2025","journal-title":"Cell Rep"},{"key":"10.1016\/j.jare.2026.08.030_b0190","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyag155","article-title":"KRAS G12R in pancreatic cancer: why this mutation resists current inhibitor strategies","volume":"31","author":"Kern","year":"2026","journal-title":"Oncologist"},{"key":"10.1016\/j.jare.2026.08.030_b0195","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1158\/0008-5472.CAN-25-2630","article-title":"KRASG12R-mutant pancreatic cancer features limited ERK\/MAPK transcriptional activity and a distinctive tumor microenvironment","volume":"86","author":"Burge","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0200","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41698-025-01166-3","article-title":"KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials","volume":"9","author":"Navarro-Jim\u00e9nez","year":"2025","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0205","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12943-025-02343-5","article-title":"Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer","volume":"24","author":"Hwang","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jare.2026.08.030_b0210","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0215","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p. G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.08.030_b0220","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS G12C solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0225","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non\u2013small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.08.030_b0230","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"De","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jare.2026.08.030_b0235","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jare.2026.08.030_b0240","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jare.2026.08.030_b0245","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1158\/2159-8290.CD-24-1885","article-title":"Beyond first-generation KRAS inhibitors: BBO-8520 tests the dual mechanism hypothesis","volume":"15","author":"Zhou","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2026.08.030_b0250","unstructured":"D3 Bio Inc. D3 Bio, Inc. Announces FDA breakthrough therapy designation and orphan drug designation for D3S-001 for the treatment of patients with KRAS G12C\u2013mutated cancers 2025."},{"key":"10.1016\/j.jare.2026.08.030_b0255","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1158\/2159-8290.CD-24-0006","article-title":"D3S-001, a KRAS G12C inhibitor with rapid target engagement kinetics, overcomes nucleotide cycling, and demonstrates robust preclinical and clinical activities","volume":"14","author":"Zhang","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2026.08.030_b0260","unstructured":"ClinicalTrials.gov. A study of D3S-001 monotherapy or combination therapy in subjects with advanced solid tumors with a KRAS p.G12C Mutation 2025"},{"key":"10.1016\/j.jare.2026.08.030_b0265","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/s41591-025-03688-6","article-title":"D3S-001 in advanced solid tumors with KRAS G12C mutations: a phase 1 trial","volume":"31","author":"Cho","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jare.2026.08.030_b0270","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1021\/acs.jmedchem.4c02313","article-title":"Discovery of elironrasib (RMC-6291), a potent and orally bioavailable, RAS (ON) G12C-selective, covalent tricomplex inhibitor for the treatment of patients with RAS G12C-addicted cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.jare.2026.08.030_b0275","doi-asserted-by":"crossref","first-page":"PR014","DOI":"10.1158\/1535-7163.TARG-23-PR014","article-title":"Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C (ON) inhibitor, in patients with or without prior KRASG12C (OFF) inhibitor treatment","volume":"22","author":"J\u00e4nne","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jare.2026.08.030_b0280","unstructured":"Revolution Medicines Inc. Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib (RMC-6291) in KRAS G12C-Mutant NSCLC 2025."},{"key":"10.1016\/j.jare.2026.08.030_b0285","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1158\/2159-8290.CD-24-0840","article-title":"Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C","volume":"15","author":"Maciag","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2026.08.030_b0290","unstructured":"ClinicalTrials.gov. ONKORAS-101: A study of BBO-8520 \u00b1 pembrolizumab in KRAS G12C-mutated non\u2013small cell lung cancer (Identifier NCT06343402) 2024."},{"key":"10.1016\/j.jare.2026.08.030_b0295","unstructured":"Study Details | NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT06040541 (accessed June 30, 2026)."},{"key":"10.1016\/j.jare.2026.08.030_b0300","unstructured":"Study details | NCT06162221 | study of RAS(ON) inhibitors in patients with advanced RAS-mutated NSCLC | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT06162221 (accessed June 30, 2026)."},{"key":"10.1016\/j.jare.2026.08.030_b0305","unstructured":"Study details | NCT06445062 | study of RAS(ON) inhibitors in patients with gastrointestinal solid tumors | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT06445062 (accessed June 30, 2026)."},{"key":"10.1016\/j.jare.2026.08.030_b0310","unstructured":"Study details | NCT06520488 | A study of HRS-4642 in combination with antineoplastic agents in advanced solid tumors | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT06520488 (accessed July 8, 2026)."},{"key":"10.1016\/j.jare.2026.08.030_b0315","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","article-title":"Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer","volume":"629","author":"Wasko","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.08.030_b0320","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2026.08.030_b0325","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1200\/JCO.2025.43.4_suppl.722","article-title":"Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)","volume":"43","author":"Garrido-Laguna","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0330","doi-asserted-by":"crossref","first-page":"LB218","DOI":"10.1158\/1538-7445.AM2025-LB218","article-title":"Abstract LB218: early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)","volume":"85","author":"Luo","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0335","unstructured":"Revolution Medicines Inc. Revolution medicines announces FDA breakthrough therapy designation for daraxonrasib in previously treated metastatic pancreatic cancer with KRAS G12 mutations 2025."},{"key":"10.1016\/j.jare.2026.08.030_b0340","unstructured":"Revolution Medicines Inc. RAS(ON) multi-selective inhibitor daraxonrasib granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer 2025"},{"key":"10.1016\/j.jare.2026.08.030_b0345","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2605555","article-title":"Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer","author":"O\u2019Reilly","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.08.030_b0350","doi-asserted-by":"crossref","first-page":"CT215","DOI":"10.1158\/1538-7445.AM2026-CT215","article-title":"Abstract CT215: RASolve 301: a phase 3 study of daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC","volume":"86","author":"Skoulidis","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0355","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/0008-5472.CAN-24-0323","article-title":"A pan-RAS inhibitor with a unique mechanism of action blocks tumor growth and induces antitumor immunity in gastrointestinal cancer","volume":"85","author":"Foote","year":"2025","journal-title":"Cancer Res"},{"issue":"1866\u20131884","key":"10.1016\/j.jare.2026.08.030_b0360","first-page":"e12","article-title":"A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers","volume":"43","author":"Feng","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2026.08.030_b0365","doi-asserted-by":"crossref","first-page":"CT019","DOI":"10.1158\/1538-7445.AM2025-CT019","article-title":"Abstract CT019: preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS (ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors","volume":"85","author":"Arbour","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0370","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12943-025-02288-9","article-title":"ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma","volume":"24","author":"Bandi","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jare.2026.08.030_b0375","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol Biomed"},{"key":"10.1016\/j.jare.2026.08.030_b0380","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.jare.2026.08.030_b0385","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS (G12D) selective degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun Chem"},{"key":"10.1016\/j.jare.2026.08.030_b0390","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1016\/j.annonc.2024.08.675","article-title":"608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)","volume":"35","author":"Park","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0395","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa2600752","article-title":"Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer","volume":"394","author":"Park","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.08.030_b0400","doi-asserted-by":"crossref","DOI":"10.1021\/jacs.5c10354","article-title":"Identification of a highly cooperative PROTAC degrader targeting GTP-loaded KRAS (on) alleles","author":"Vetma","year":"2025","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jare.2026.08.030_b0405","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS3178","article-title":"Trial in progress: phase 1 study of the selective protein degrader ASP4396 in patients with locally advanced or metastatic solid tumors with KRAS G12D mutations","volume":"43","author":"Sen","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0410","unstructured":"ClinicalTrials.gov. A study to find a suitable dose of ASP5834 in adults with solid tumors 2025."},{"key":"10.1016\/j.jare.2026.08.030_b0415","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1158\/1538-7445.AM2025-7010","article-title":"HDB-82: A promising PROTAC degrader for KRAS G12D mutant cancers","volume":"85","author":"Baig","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0420","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1538-7445.AM2025-1662","article-title":"Preclinical studies of RP04340: an orally available and potent PROTAC compound targeting KRAS G12C\/D\/V mutant tumors","volume":"85","author":"Ji","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0425","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.1158\/1538-7445.AM2025-6376","article-title":"KRASmultidegrader BPI-585725 displays potent anti-tumor activity in KRAS-driven preclinical models","volume":"85","author":"Li","year":"2025","journal-title":"Cancer Res"},{"issue":"19\u201331","key":"10.1016\/j.jare.2026.08.030_b0430","first-page":"e6","article-title":"Exploring targeted degradation strategy for oncogenic KRASG12C","volume":"27","author":"Zeng","year":"2020","journal-title":"Cell Chem Biol"},{"issue":"385","key":"10.1016\/j.jare.2026.08.030_b0435","first-page":"1338","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"2024","author":"Popow","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.jare.2026.08.030_b0440","unstructured":"Study Details | NCT07409272 | A study to evaluate the effectiveness and safety of setidegrasib, given with either mFOLFIRINOX or NALIRIFOX chemotherapies, in people with pancreatic cancer | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT07409272 (accessed June 29, 2026)."},{"key":"10.1016\/j.jare.2026.08.030_b0445","unstructured":"Study Details | NCT07566052 | a study to compare setidegrasib (ASP3082) with docetaxel, in people with non-small cell lung cancer with a KRAS G12D mutation | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT07566052 (accessed June 30, 2026)."},{"key":"10.1016\/j.jare.2026.08.030_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2026.115775","article-title":"Rational modification of PROTACs for tumor-selective protein degradation","volume":"230","author":"Fu","year":"2026","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jare.2026.08.030_b0455","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jconrel.2024.11.076","article-title":"PROTAC delivery in tumor immunotherapy: where are we and where are we going?","volume":"378","author":"Li","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.jare.2026.08.030_b0460","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/pharmaceutics17040501","article-title":"PROTAC delivery strategies for overcoming physicochemical properties and physiological barriers in targeted protein degradation","volume":"17","author":"Syahputra","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jare.2026.08.030_b0465","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-25-0349","article-title":"Response and resistance to RAS inhibition in cancer","author":"Ebright","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2026.08.030_b0470","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jare.2026.08.030_b0475","article-title":"Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jare.2026.08.030_b0480","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-026-10374-x","article-title":"Dual targeting of glutamine metabolism and lysosomal function in eliminating drug-tolerant KRAS-mutant cancer cells","author":"Furukawa","year":"2026","journal-title":"Commun Biol"},{"key":"10.1016\/j.jare.2026.08.030_b0485","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47423-0","article-title":"Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer","volume":"15","author":"Haderk","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.08.030_b0490","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41698-024-00793-6","article-title":"Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization","volume":"9","author":"Maruyama","year":"2025","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0495","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12943-024-02157-x","article-title":"The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer","volume":"23","author":"McDaid","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jare.2026.08.030_b0500","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2026.08.030_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218194","article-title":"SRC at the crossroads of KRAS inhibitor resistance: mechanisms and therapeutic opportunities","volume":"639","author":"Tian","year":"2026","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jare.2026.08.030_b0510","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq4274","article-title":"SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition","volume":"10","author":"Song","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.jare.2026.08.030_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216692","article-title":"AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells","volume":"587","author":"Morimoto","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jare.2026.08.030_b0520","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.178535","article-title":"YAP\/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5\/mTOR axis","volume":"9","author":"Yang","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.jare.2026.08.030_b0525","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70458","article-title":"Persistent lineage plasticity driving lung cancer development and progression","volume":"15","author":"Meng","year":"2025","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.jare.2026.08.030_b0530","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1158\/1538-7445.AM2025-4426","article-title":"Chromatin constraints underpin adeno-to-squamous cell state transitions during acquired resistance to KRAS inhibition","volume":"85","author":"Patel","year":"2025","journal-title":"Cancer Res"},{"issue":"413\u2013428","key":"10.1016\/j.jare.2026.08.030_b0535","first-page":"e7","article-title":"Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer","volume":"42","author":"Tong","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2026.08.030_b0540","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2025.1537523","article-title":"Sotorasib resistance triggers epithelial-mesenchymal transition and activates AKT and P38-mediated signaling","volume":"12","author":"Megid","year":"2025","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jare.2026.08.030_b0545","doi-asserted-by":"crossref","first-page":"B120","DOI":"10.1158\/1538-7445.PANCREATIC25-B120","article-title":"Abstract B120: mapping and modulating epithelial-mesenchymal plasticity under RAS (ON) multi-selective inhibition in PDAC through lineage tracing and Perturb-seq","volume":"85","author":"Dilly","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0550","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccell.2025.10.010","article-title":"Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer","volume":"44","author":"Zhang","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2026.08.030_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217258","article-title":"Macroautophagy\/autophagy promotes resistance to KRASG12D-targeted therapy through glutathione synthesis","volume":"604","author":"Han","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jare.2026.08.030_b0560","doi-asserted-by":"crossref","first-page":"B101","DOI":"10.1158\/1538-7445.PANCREATIC25-B101","article-title":"Abstract B101: TNFR-MK2 signaling drives autophagy and resistance to KRAS\/MAPK inhibition in pancreatic cancer","volume":"85","author":"Pereye","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0565","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1158\/1538-7445.AM2024-4322","article-title":"Inhibition of ULK and KRASG12C control tumor growth in preclinical models of lung cancer","volume":"84","author":"Ghazi","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0570","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/15548627.2018.1450708","article-title":"Autophagic reliance promotes metabolic reprogramming in oncogenic KRAS-driven tumorigenesis","volume":"14","author":"Lin","year":"2018","journal-title":"Autophagy"},{"key":"10.1016\/j.jare.2026.08.030_b0575","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-SY13-01","article-title":"Abstract SY13-01: targeting the metabolic basis of resistance to Kras signaling inhibition in pancreatic cancer","volume":"85","author":"Singh","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0580","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-24-1984","article-title":"KRAS signaling inhibition induces a targetable metabolic dependency on lipophagy-dependent fatty acid oxidation in pancreatic cancer","author":"Thakur","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0585","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1538-7445.AM2025-6764","article-title":"Lipophagy-dependent fatty acid oxidation is a metabolic vulnerability for KRAS signaling inhibition in pancreatic cancer","volume":"85","author":"Zhao","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0590","article-title":"Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors","volume":"381","author":"Lv","year":"2023","journal-title":"Science (1979)"},{"key":"10.1016\/j.jare.2026.08.030_b0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218684","article-title":"Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK\/ERK-mediated unfolded protein response in pancreatic cancer","author":"Xue","year":"2026","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jare.2026.08.030_b0600","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41698-026-01553-4","article-title":"Targeting WFS1 overcomes KRASG12D dependency and adaptive resistance to KRAS inhibition in pancreatic cancer","volume":"10","author":"Chen","year":"2026","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0605","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41420-025-02878-y","article-title":"Bidirectional crosstalk between ER stress and lipid metabolism: from proteostasis to tumor adaptation","volume":"12","author":"Wu","year":"2026","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jare.2026.08.030_b0610","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1158\/1538-7445.AM2024-3335","article-title":"A novel and potent IRE1\u03b1 RNase inhibitor, HM100168 as a promising therapeutic strategy in solid cancers","volume":"84","author":"Kim","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114059","article-title":"Endoplasmic reticulum-targeted strategies for programmed cell death in cancer therapy: approaches and prospects","volume":"385","author":"Liang","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.jare.2026.08.030_b0620","doi-asserted-by":"crossref","first-page":"8895","DOI":"10.1038\/s41467-024-53039-1","article-title":"Targeting IRE1\u03b1 reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer","volume":"15","author":"Unal","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.08.030_b0625","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1158\/1538-7445.AM2025-419","article-title":"Chromosomal instability and oncogene dosage variations underlying KRAS G12C inhibition therapy resistance in lung cancer","volume":"85","author":"Gao","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0630","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/cas.16441","article-title":"Mechanisms of resistance to KRAS inhibitors: cancer cells\u2019 strategic use of normal cellular mechanisms to adapt","volume":"116","author":"Tanaka","year":"2025","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jare.2026.08.030_b0635","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1200\/JCO.2025.43.16_suppl.3540","article-title":"Biomarkers of emergent resistance to sotorasib plus panitumumab in KRAS G12C-mutated metastatic colorectal cancer (mCRC) from the randomized, phase 3 CodeBreaK 300 study","volume":"43","author":"Salvatore","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0640","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS (G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.08.030_b0645","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0650","doi-asserted-by":"crossref","first-page":"7554","DOI":"10.1038\/s41467-024-51828-2","article-title":"RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade","volume":"15","author":"Nokin","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.08.030_b0655","doi-asserted-by":"crossref","unstructured":"Kar S, Zhuang Y, Ahler E, Lai LP, Starodub A, Spira A, et al. Mechanisms of resistance to the RAS (ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS (ON) combination therapies. AACR, vol. 85, 2025.","DOI":"10.1158\/1538-7445.AM2025-LB281"},{"key":"10.1016\/j.jare.2026.08.030_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216904","article-title":"Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors","volume":"591","author":"Choi","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jare.2026.08.030_b0665","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-25-0483","article-title":"Resistance to the KRASG12D inhibitor MRTX1133 is associated with increased sensitivity to BET inhibition","author":"Principe","year":"2026","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jare.2026.08.030_b0670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-025-14033-y","article-title":"The complex journey of targeting RAS in oncology","volume":"25","author":"Wasiak","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jare.2026.08.030_b0675","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated metastatic colorectal cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2026.08.030_b0680","unstructured":"FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer | FDA n.d. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer (accessed June 30, 2026)."},{"key":"10.1016\/j.jare.2026.08.030_b0685","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.08.030_b0690","article-title":"A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C\u2013mutated metastatic colorectal cancer (CodeBreaK 301)","volume":"43","author":"Kim","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105074","article-title":"Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis","volume":"102","author":"Ernst","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jare.2026.08.030_b0700","unstructured":"ClinicalTrials.gov. Study of RMC-6291 in combination with RMC-6236 in participants with advanced KRAS G12C mutant solid tumors (Identifier NCT06128551) 2023."},{"key":"10.1016\/j.jare.2026.08.030_b0705","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2523039122","article-title":"A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance","volume":"122","author":"Liaki","year":"2025","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jare.2026.08.030_b0710","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.2026.44.2_suppl.756","article-title":"Effect of ROCK2 signaling on resistance to KRAS inhibitors in pancreatic cancer","volume":"44","author":"Marinelarena","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0715","doi-asserted-by":"crossref","first-page":"8146","DOI":"10.1038\/s41467-024-52324-3","article-title":"Combining RAS (ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade","volume":"15","author":"Anastasiou","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.08.030_b0720","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/s43018-024-00800-6","article-title":"Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance","volume":"5","author":"Thatikonda","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jare.2026.08.030_b0725","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13046-025-03616-z","article-title":"CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer","volume":"45","author":"Mulero-S\u00e1nchez","year":"2026","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0730","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-25-1507","article-title":"Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer","volume":"85","author":"Drizyte-Miller","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0735","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","article-title":"Exploiting the therapeutic implications of KRAS inhibition on tumor immunity","volume":"42","author":"Molina-Arcas","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jare.2026.08.030_b0740","doi-asserted-by":"crossref","unstructured":"Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nature Medicine 2025 31:11 2025;31:3648\u201353. doi: 10.1038\/s41591-025-03876-4.","DOI":"10.1038\/s41591-025-03876-4"},{"key":"10.1016\/j.jare.2026.08.030_b0745","doi-asserted-by":"crossref","unstructured":"Chung V, Devoe CE, George TJ, Welkowsky E, Kheoh T, Haqq CM, et al. AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma. Journal of Clinical Oncology 2024;42:TPS720. doi: 10.1200\/JCO.2024.42.3_suppl.TPS720.","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS720"},{"key":"10.1016\/j.jare.2026.08.030_b0750","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jare.2026.08.030_b0755","doi-asserted-by":"crossref","first-page":"CT036","DOI":"10.1158\/1538-7445.AM2023-CT036","article-title":"Abstract CT036: Safety and immunogenicity of a first-in-human mutant KRAS long peptide vaccine combined with ipilimumab\/nivolumab in resected pancreatic cancer: preliminary analysis from a phase I study","volume":"83","author":"Haldar","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0760","doi-asserted-by":"crossref","unstructured":"Huff AL, Haldar SD, Gergis AA, Wang HH, Danilova L, Heumann T, et al. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Nat Commun 2026;17:1538-. doi: 10.1038\/s41467-026-68324-4.","DOI":"10.1038\/s41467-026-74711-8"},{"key":"10.1016\/j.jare.2026.08.030_b0765","doi-asserted-by":"crossref","first-page":"CT264","DOI":"10.1158\/1538-7445.AM2025-CT264","article-title":"Abstract CT264: mutant KRAS peptide vaccine combined with ipilimumab\/nivolumab in advanced mismatch repair proficient\/microsatellite stable (MMRp\/MSS) colorectal cancer: preliminary analysis from a phase I study","volume":"85","author":"Wang","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0770","article-title":"A phase Ib study of a pooled synthetic long peptide mutant KRAS vaccine combined with balstilimab\/botensilimab in metastatic pancreatic cancer and metastatic MMR-proficient colorectal cancer in the maintenance setting","volume":"43","author":"Liang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0775","doi-asserted-by":"crossref","first-page":"LB352","DOI":"10.1158\/1538-7445.AM2024-LB352","article-title":"Abstract LB352: unraveling therapeutic potentials of mRNA-based cancer vaccine concurrently targeting heterogeneous KRAS mutant cancer","volume":"84","author":"Lim","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0780","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e14672","article-title":"Development of an arenavirus-based immunotherapy for treatment of KRAS mutant cancer","author":"Raguz","year":"2024","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0785","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1158\/1538-7445.AM2025-3795","article-title":"Cross-HLA targeting of synthetic neoepitopes with T cell engagers to eradicate sotorasib-resistant, KRAS-G12C mutant cancer","volume":"85","author":"Stopfer","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0790","article-title":"Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery","volume":"5","author":"Conn","year":"2025","journal-title":"Cell Rep Methods"},{"key":"10.1016\/j.jare.2026.08.030_b0795","doi-asserted-by":"crossref","first-page":"B029","DOI":"10.1158\/2326-6074.TUMIMM23-B029","article-title":"Abstract B029: investigating therapeutic strategies to promote immune rejection of KRAS G12C inhibitor-resistant sub-populations in lung cancer","volume":"11","author":"Tomaschko","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jare.2026.08.030_b0800","unstructured":"Study Details | NCT04613596 | phase 2 trial of adagrasib monotherapy and in combination with pembrolizumab and a phase 3 trial of adagrasib in combination in patients with a KRAS G12C mutation KRYSTAL-7 | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT04613596 (accessed June 30, 2026)."},{"key":"10.1016\/j.jare.2026.08.030_b0805","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1556-0864(25)00200-X","article-title":"5MO: First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced\/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) and PD-L1 \u226550% from the phase II portion of KRYSTAL-7","volume":"20","author":"J\u00e4nne","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0810","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6074.IO2025-PR012","article-title":"Abstract PR012: The RAS(ON) G12D-selective inhibitor RMC-9805 synergizes with anti-PD-1 to extend durability of antitumor activity in KRAS G12D-driven preclinical cancer models","volume":"13","author":"Menard","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jare.2026.08.030_b0815","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/1078-0432.CCR-25-0821","article-title":"KRAS inhibitors in pancreas cancer: facts and hopes about the immunotherapy we have all been waiting for","volume":"32","author":"Stanger","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0820","article-title":"Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial","volume":"2026","author":"Wang","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.08.030_b0825","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1753180","article-title":"Unveiling the tumor microenvironment in colorectal cancer therapeutic resistance","volume":"13","author":"Han","year":"2026","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jare.2026.08.030_b0830","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41571-025-01077-z","article-title":"The tumour microenvironment in pancreatic cancer - new clinical challenges, but more opportunities","volume":"22","author":"Kung","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jare.2026.08.030_b0835","doi-asserted-by":"crossref","first-page":"A121","DOI":"10.1158\/1538-7445.PANCREATIC25-A121","article-title":"Abstract A121: dual mechanism nanomedicine targeting drug resistance in pancreatic ductal adenocarcinoma (PDAC)","volume":"85","author":"Teng","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0840","doi-asserted-by":"crossref","first-page":"A077","DOI":"10.1158\/1538-7445.PANCREATIC25-A077","article-title":"Abstract A077: cancer-associated fibroblast (CAF) crosstalk with tumor cells bypasses cellular senescence and dampens responses to RAS pathway targeted therapy in PDAC","volume":"85","author":"Ma","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.jare.2026.08.030_b0845","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/2159-8290.CD-19-0597","article-title":"Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer","volume":"10","author":"Hou","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jare.2026.08.030_b0850","unstructured":"Study Details | NCT06252649 | study of sotorasib, panitumumab and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb in treatment-na\u00efve participants with metastatic colorectal cancer with KRAS p.G12C Mutation | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT06252649 (accessed June 29, 2026)."}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123226006624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123226006624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:03:37Z","timestamp":1791018217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123226006624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":170,"alternative-id":["S2090123226006624"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2026.08.030","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From KRAS inhibition to tumor adaptation: mechanistic layers of resistance and therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2026.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}